Silence Therapeutics announced Phase 2 success for divesiran in polycythemia vera, setting up a move into Phase 3 for the gene-silencing therapy. In the 48-patient trial, Silence said 88% of patients achieved a clinical response on divesiran across dosing intervals of every six or 12 weeks, versus 19% with placebo. Silence characterized the result as meeting the primary endpoint, strengthening the case for continued development of the siRNA candidate. The company positioned the readout as a potential differentiator in a crowded treatment landscape where controlling red blood cell levels is central to reducing thrombotic and bleeding risk. —